Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
Henan Cancer Hospital
Sichuan University
Guangzhou University of Traditional Chinese Medicine
The First Hospital of Jilin University
University Hospital Ostrava
Radiotherapy Oncology Centre "Santa Maria" Hospital
Fondazione IRCCS Policlinico San Matteo di Pavia
Tongji University
National Cancer Institute, Naples
Henan Provincial People's Hospital
Tianjin Medical University Cancer Institute and Hospital
Fuzhou General Hospital
Sichuan Cancer Hospital and Research Institute
Tianjin Medical University Cancer Institute and Hospital
Second Xiangya Hospital of Central South University
Immunicom Inc
The Second Affiliated Hospital of Shandong First Medical University
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Zhejiang Cancer Hospital
Betta Pharmaceuticals Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Beijing Chest Hospital
Peking Union Medical College Hospital
Qilu Pharmaceutical Co., Ltd.
The First Hospital of Jilin University
Shanghai Chest Hospital
Guizhou Medical University
Nanfang Hospital, Southern Medical University
Ain Shams University
The First Affiliated Hospital of Dalian Medical University
Shanghai Pulmonary Hospital, Shanghai, China
SciClone Pharmaceuticals
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Hunan Province Tumor Hospital
Betta Pharmaceuticals Co., Ltd.
AHS Cancer Control Alberta
Zhejiang University
National Cancer Institute (NCI)
ChineseAMS
Xijing Hospital
National Cancer Center, Korea